SEC Tracker
Get the app

SAB Biotherapeutics SABS

SAB Biotherapeutics gets FDA Fast Track for T1D treatment

Form
8-K
Filed
Importance
Routine
  1. FDA grants Fast Track to SAB-142 for Stage 3 T1D
  2. SAB-142 is a disease-modifying immunotherapy
  3. Phase 2b trial SAFEGUARD to complete enrollment in Q4 2026
  4. Topline data expected in 2H 2027

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when SAB Biotherapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. XBiotech XBIT public float $77M, Jun 30, 2025
  2. Oramed Pharmaceuticals ORMP public float $78M, Jun 30, 2025
  3. Inovio Pharmaceuticals INO public float $74M, Jun 30, 2025
  4. Macrogenics MGNX public float $74M, Jun 30, 2025
  5. Volitionrx VNRX public float $73M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.